Novel risk loci in LGI1-antibody encephalitis: genome-wide association study discovery and validation cohorts.
Binks SNM., Elliott KS., Muñiz-Castrillo S., Gilbert E., Kawasaki de Araujo T., Harper AR., Brown AC., Chong AY., Band G., Peris Sempere V., Pinto A-L., Costantino F., Rayner NW., Mentzer AJ., Delanty N., Rogemond V., Picard G., Handel AE., Melzer N., Titulaer MJ., Lee S-T., Leypoldt F., Kuhlenbaeumer G., Honnorat J., Mignot E., Cavelleri GL., Knight JC., Irani SR.
Encephalitis with antibodies to leucine-rich glioma-inactivated 1 (LGI1-Ab-E) is a common form of autoimmune encephalitis, presenting with seizures and neuropsychiatric changes, predominantly in older males. More than 90% of patients carry the human leucocyte antigen (HLA) class II allele, HLA-DRB1*07:01. However, this is also present in 25% of healthy controls. Therefore, we hypothesised the presence of additional genetic predispositions. In this genome-wide association study and meta-analysis, we studied a discovery cohort of 131 French LGI1-Ab-E and a validation cohort of 126 American, British and Irish LGI1-Ab-E patients, ancestry-matched to 2613 and 2538 European controls, respectively. Outside the known major HLA signal, we found two single nucleotide polymorphisms (SNPs) at genome-wide significance (p < 5 x 10-8), implicating PTPRD, a protein tyrosine phosphatase, and LINC00670, a non-protein coding RNA gene. Meta-analysis defined four additional non-HLA loci, including the protein coding COBL gene. Polygenic risk scores with and without HLA variants proposed a contribution of non-HLA loci. In silico network analyses suggested LGI1 and PTPRD mediated interactions via the established receptors of LGI1, ADAM22 and ADAM23. Our results identify new genetic loci in LGI1-Ab-E. These findings present opportunities for mechanistic studies and offer potential markers of susceptibility, prognostics and therapeutic responses.